Glycosylation as a strategy to improve antibody-based therapeutics

Nature Reviews Drug Discovery

Volumn 8, Issue 3, 2009, Pages 226-234

  Jefferis, Roy ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASPARAGINE; CD16 ANTIGEN; CELL SURFACE PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC GAMMA RECEPTOR I; FC GAMMA RECEPTOR II; FC RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; LENERCEPT; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; RECOMBINANT ANTIBODY; RITUXIMAB; TENEFUSE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELL SURFACE; CHROMOSOME 1Q; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG ANALYSIS; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SCREENING; DRUG SPECIFICITY; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; STRUCTURAL HOMOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; NEOPLASMS; OLIGOSACCHARIDES;

EID: 61649087668     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2804     Document Type: Review

References (77)

1. Carter, P. J. Potent antibody therapeutics by design. Nature Rev. Immunol. 6, 343-357 (2006).
2. Moutel, S. & Perez, F. Antibodies - Europe. Engineering the next generation of antibodies. Biotechnol. J. 3, 298-300 (2008).
3. Reichert, J. M. & Valge-Archer, V. E. Development trends for monoclonal antibody cancer therapeutics. Nature Rev. Drug Discov. 6, 349-356 (2007).
4. Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
5. Mirik, G. R., Bradt, B. M., Denardo, S. J. & Denardo, G. L. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q. J. Nucl. Med. Mol. Imaging 48, 251-257 (2004).
6. Koren, E. et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 333, 1-9 (2008).
7. Aarden, L., Ruul, S. R. & Wolbink, G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr. Opin. Immunol. 20, 431-435 (2008).
8. Klitgaard, J. L. et al. Reduced susceptibility of recombinant polyclonal antibodies to inhibitory antivariable domain antibody responses. J. Immunol. 177, 3782-3790 (2006).
9. Woof, J. M. & Burton, D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nature Rev. Immunol. 4, 89-99 (2004).
10. Nezlin, R. & Ghetie, V. Interactions of immunoglobulins outside the antigen-combining site. Adv. Immunol. 82, 155-215 (2004).
11. Jefferis, R. Antibody therapeutics: Isotype and glycoform selection. Expert Opin. Biol. Ther. 7, 1401-1413 (2007).
12. van Sorge, N. M., van der Pol, W. L. & van de Winkel, J. G. FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61, 189-202 (2003).
13. Nimmerjahn, F. & Ravetch, J. Fcγ receptors as regulators of immune responses. Nature Rev. Immunol. 8, 34-47 (2008).
14. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21, 11-16 (2005).
15. Sinclair, A. M. & Elliott, S. J. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94, 1626-1635 (2005).
16. Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733-26740 (2002).
17. Shinkawa, T. et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 3466-3473 (2003).
18. Niwa, R. et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J. Immunol. Methods 306, 151-160 (2005).
19. Ferrara, C. et al. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnol. Bioeng. 93, 851-861 (2006).
20. Krapp, S. et al. Structural analysis of human IgG glycoforms reveals a correlation between oligosaccharide content, structural integrity and Fcγ-receptor affinity. J. Mol. Biol. 325, 979-989 (2003).
21. Deisenhofer, J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20, 2361-2370 (1981).
22. Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. & Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007).
23. Mizuochi, T., Taniguchi, T. Shimizu, A. & Kobata, A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J. Immunol. 129, 2016-2020 (1982).
24. Routier, F. H. et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: A critical evaluation of different methods. J. Immunol. Methods 213, 13-30 (1998).
25. Kaneko, Y., Nimmerjahn, F. & Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 670-673 (2006).
26. Scallon, B., Tam, S. H., McCarthy, S. G., Cai, A. N. & Raju, T. S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44, 1524-1534 (2007).
27. Nimmerjahn, F. & Ravetch, J. V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204, 11-15 (2007).
28. Anthony, R. M. et al. Recapitulation of IVIG antiinflammatory activity with a recombinant IgG Fc. Science 320, 373-376 (2008).
29. Jefferis, R. et al. A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem. J. 268, 529-537 (1990).
30. Farooq, M., Takahashi N., Arrol, H., Drayson, M. & Jefferis, R. Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconjugate J. 14, 489-492 (1997).
31. Youings, A. et al. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem. J. 314, 621-630 (1996).
32. Holland, M. et al. Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA associated systemic vasculitis. Biochim. Biophys. Acta 1760, 669-677 (2006).
33. Mimura, Y., Ashton, P. R., Takahashi, N., Harvey, D. J. & Jefferis, R. Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. J. Immunol. Methods 326, 116-126 (2007).
34. Mimura, Y. et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: Properties of a series of truncated glycoforms. Mol. Immunol. 37, 697-706 (2000).
35. Birch, J. R. & Racher, A. J. Antibody production. Adv. Drug Deliv. Rev. 58, 671-685 (2006).
36. Imai-Nishiya, H. et al. Double knockdown of α1, 6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase ( GMD) in antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC. BMC Biotechnol. 7, 84 (2007).
37. Macher, B. A. & Galili, U. The Galα1,3Galβ1, 4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevance. Biochim. Biophys. Acta 1780, 75-88 (2008).
38. Padler-Karavani, V. et al. Diversity in specificity, abundance and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. Glycobiology 18, 818-830 (2008).
39. Qian, J. et al. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 364, 8-18 (2007).
40. Chung, C. H. et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 358, 1109-1117 (2008).
41. Huang, L., Biolosi, S., Bales, K. R. & Kuchibhotla, U. Impact of variable domain glycosylation on antibody clearance: An LC/MS characterization. Anal. Biochem. 349, 197-207 (2006).
42. Carter, P. et al., Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
43. Lim, A., Reed-Bogan, A. & Harmon, B. J. Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. Anal. Biochem. 375 163-172 (2008).
44. Desjarlais, J. R., Lazar, G. A., Zhukovsky E. A. & Chu, S. Y. Optimizing engagement of the immune system by anti-tumor antibodies: An engineer's perspective. Drug Discov. Today 12, 898-910 (2007).
45. Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-Å crystal structure of the human IgG1 Fc-Fc.RIII complex. Nature 406, 267-273 (2000).
46. Radaev, S. et al. The structure of human type FcγIII receptor in complex with Fc. J. Biol. Chem. 276, 16469-16477 (2001).
47. Mimura, Y. et al. The role of oligosaccharide residues of IgG1-Fc in FcγIIb binding. J. Biol. Chem. 276, 5539-45547 (2001).
48. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
49. Watier, H. Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins. Expert Opin. Biol. Ther. 5 (Suppl. 1), S1-S8 (2005).
50. Marcus, R. & Hagenbeek, A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol. 78 (Suppl. 67), 5-14 (2007).
51. Lifely, M. R., Hale, G. & Boyse, S. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5, 813-822 (1995).
52. Umana, P. et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody dependent cellular cytotoxic activity. Nature Biotechnol. 17, 176-180 (1999).
53. Davies, J. et al. Expression of GTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies of altered glycoforms leads to an increase in ADCC thro' higher affinity for FcRIII. Biotechnol. Bioeng. 74, 288-294 (2001).
54. Ymane-Ohuki, N. et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87, 614-622 (2004).
55. Iida, S. et al. Non-fucosylated therapeutic IgG antibody can evade the inhibitory effect of serum IgG on antibody-dependent cellular cytotoxicity through its binding to FcγRIIIa. Clin. Cancer Res. 12, 2879-2887 (2006).
56. Preithner, S. et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for the inhibition of ADCC by excess endogenous immunoglobulin G. Mol. Immunol. 43, 1183-1193 (2006).
57. Nechansky, A. et al. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol. Immunol. 44 1815-1817 (2007).
58. Suzuki, E. et al. Nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res. 13, 1875-1882 (2007).
59. Peipp, M. et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112 2390-2399 (2008).
60. Ferarra, C., Stuart, F., Sondermann, P., Brunker, P. & Umana, P. The carbohydrate at FcγaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J. Biol. Chem. 281, 5032-5036 (2006).
61. Boyd, P. N., Lines, A. C. & Patel, A. K. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol. Immunol. 32, 1311-1318 (1995).
62. US Food and Drug Administration (FDA). Memorandum. FDA web site [online], http://www.fda.gov/cder/biologics/review/ ritugen112697-r2.pdf (1997).
63. Malhotra, R. et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Med. 1, 237-243 (1995).
64. Abadeh, S. et al. Remodelling the oligosaccharide of human IgG antibodies: Effects on biological activities. Biochem. Soc. Trans. 25, S661 (1997).
65. Arnold, J. N., Dwek, R. A., Rudd, P. M. & Sim, R. B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol. Lett. 106, 103-110 (2006).
66. Garred, P. et al. J. Two edged role of mannose binding lectin in rheumatoid arthritis: A cross sectional study. J. Rheumatol. 27 26-34 (2000).
67. Sato, R. et al. Substances reactive with mannose-binding protein (MBP) in sera of patients with rheumatoid arthritis. Fukushima J. Med. Sci. 43, 99-111 (1997).
68. Saevarsdottir, S., Vikingsdottir, T. & Valdimarsson, H. The potential role of mannan-binding lectin in the clearance of self-components including immune complexes. Scand. J. Immunol. 60, 23-29 (2004).
69. Taylor, M. E. & Drickamer, K. Paradigms for glycan-binding receptors in cell adhesion. Curr. Opin. Cell Biol. 19, 572-577 (2007).
70. Vyas, J. M., Van der Veen, A. G., & Ploegh, H. L. The known unknowns of antigen processing and presentation. Nature Rev. Immunol. 8, 607-618 (2008).
71. Roopenian, D. C. & Akilesh, S. FcRn: The neonatal Fc receptor comes of age. Nature Rev. Immunol. 7, 715-725 (2007).
72. Harris, R. J. Heterogeneity of recombinant antibodies: Linking structure to function. Dev. Biol. (Basel) 122, 117-127 (2005).
73. Jones, A. J. et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17 529-540 (2007).
74. Keck, R. et al. Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N acetylglucosamine content. Biologicals 36, 49-60 (2008).
75. Edberg, J. C. & Kimberly, R. P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): Differential ligand binding. J. Immunol. 159, 3849-3857 (1997).
76. Watt, G. et al. Synthesis of homogeneous neoglycoforms of IgG-Fc molecules and their functional properties. Hum. Antibodies 11 29-30 (2002).
77. Zhou, Q. et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol. Bioeng. 99, 652-665 (2008).